No, it is necessary to fill out the risk assessment form in the guideline.
No, the higher standard must be chosen in case there is more than one option.
The manufacturer should fill out the risk assessment form
Authorized Representative (AR) should respond to SFDA with any remarks and justifications within the specified period.
If users are not responding to the Authorized Representative (AR) or the supplier in regards to implementing the corrective or preventive action and evidence is provided, the necessary actions will be taken to ensure safe use of the medical device.
According to requirements and standards of the approved quality management system in the manufacturer.
The Annex specifies the requested information in the Field Safety Notice, other information may be added by the manufacturer, according to the type of the problem and the corrective or preventive actions to reduce or remove a risk.
Yes, manufacturer through its Authorized Representative (AR) or importer shall report to the SFDA any Field Safety Corrective Action when the KSA is affected within (2) working days from Field Safety Corrective Action issuance date by manufacturer
Yes, KSA is considered as not affected.